Development of a novel biologic showing downregulation of immune responses, suppression of bone destruction and retention in the target site.
| Project/Area Number |
16K15654
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthopaedic surgery
|
|---|
| Research Institution | The University of Tokyo |
|---|
Principal Investigator |
Honma Masashi 東京大学, 医学部附属病院, 講師 (60401072)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 免疫学 / 骨代謝 / シグナル伝達 / 生理活性 |
|---|
| Outline of Final Research Achievements |
Outcomes of RA treatment are recently improved due to the development of various anti-inflammatory biologics, however; there remains insufficiency from the viewpoint of protection from the bone destruction and the rate of remission induction. In the present study, we constructed a novel biologic; a tandem fusion construct of CTLA-4 extracellular domain, IgG1 Fc domain and anti-RANKL scFv. Experimental treatment of collagen-induced arthritis mice model showed that this construct exhibited stronger suppression of articular inflammation and protection from cartilage and bone destruction compared to the existing biologic abatacept.
|
Report
(3 results)
Research Products
(1 results)
